BioClinica acquires Synowledge
Wednesday, September 23, 2015
BioClinica, a specialty clinical trials services and technology provider, has acquired Synowledge to expand its offering into the growing drug safety and regulatory business process outsourcing market. Based in Miami, Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analyzing and reporting adverse drug events.
“This acquisition extends BioClinica’s solutions into an important new area for our customers,” said BioClinica President and Chief Executive Officer John Hubbard. “Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events. Its capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.”
Sankesh Abbhi, who founded Synowledge, will serve as senior vice president and head of global safety and regulatory solutions. He will report to Mukhtar Ahmed, president of BioClinica’s eClinical Solutions Division